| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer
|
Rosenberg, A.J.
|
|
|
34 |
8 |
p. 714-722
|
artikel
|
| 2 |
Corrigendum to “Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level”
|
Bazhenova, L.
|
|
|
34 |
8 |
p. 725-726
|
artikel
|
| 3 |
Costs per event averted in the neoadjuvant and adjuvant settings of early triple-negative breast cancer
|
Olivier, T.
|
|
|
34 |
8 |
p. 723-724
|
artikel
|
| 4 |
Digital therapeutics for remote symptom monitoring and management in cancer care: the current and future state
|
Basch, E.
|
|
|
34 |
8 |
p. 635-637
|
artikel
|
| 5 |
Editorial Board
|
|
|
|
34 |
8 |
p. iii
|
artikel
|
| 6 |
Erratum to “P-309 In vitro drug screening of patient-specific tumoroids to predict chemotherapeutic treatment response in pancreatic ductal adenocarcinoma: An interim analysis”
|
Nitschke, C.
|
|
|
34 |
8 |
p. 727-728
|
artikel
|
| 7 |
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
|
Tarantino, P.
|
|
|
34 |
8 |
p. 645-659
|
artikel
|
| 8 |
IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications
|
Burotto, M.
|
|
|
34 |
8 |
p. 693-702
|
artikel
|
| 9 |
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
|
Ray-Coquard, I.
|
|
|
34 |
8 |
p. 681-692
|
artikel
|
| 10 |
Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy
|
Tannock, I.F.
|
|
|
34 |
8 |
p. 638-644
|
artikel
|
| 11 |
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study
|
Oliveira, M.
|
|
|
34 |
8 |
p. 670-680
|
artikel
|
| 12 |
Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability
|
Ratovomanana, T.
|
|
|
34 |
8 |
p. 703-713
|
artikel
|
| 13 |
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial
|
Harbeck, N.
|
|
|
34 |
8 |
p. 660-669
|
artikel
|
| 14 |
Table of Contents
|
|
|
|
34 |
8 |
p. i-ii
|
artikel
|
Tijdschrift beschrijving